Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma

Author:  Scherpereel A; Grigoriu B. Conti M; et al.

Scherpereel A, Grigoriu B. Conti M, et al.
Am J Respir Crit Care Med. 2006; 173(10):1155-1160.

Scherpereel et al, tested a group of 137 patients, in which 74 had malignant pleural mesothelioma (MPM), 35 suffered from pleural metastasis of carcinomas (Mets) and 28 were diagnosed with benign pleural lesions with Asbestos Exposure (BPLAE) from hospitals throughout the northern and western regions of France. The MESOMARK assay (SMRP levels) was used to evaluate serum samples available from this group of patients. The results show a difference in SMRP levels among the three groups, in which the level of SMRP present in patients with MPM was significantly elevated, compared to other evaluated patients. This group concludes that a biomarker to help monitor disease will be a useful tool for physicians. The results of this study clearly show that SMRP values are raised significantly in patients
diagnosed with MPM.


You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Please log in to react

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.